Top-News
Montag,
16.05.2016 20:00
von
PR Newswire
| Aufrufe: 99
Escalon® Medical Corp. Reports Third Quarter Fiscal 2016 Results
Pipette und Proben (Symbolbild).
© alvarez / E+ / Getty Images
http://www.gettyimages.de
PR Newswire
WAYNE, Pa., May 16, 2016
WAYNE, Pa., May 16, 2016 /PRNewswire/ -- Escalon Medical Corp. (NASDAQ: ESMC) today announced financial results for its third quarter of fiscal 2016, ended March 31, 2016.
For the third quarter of fiscal 2016, consolidated product revenue decreased $331,000 to $3,097,000 from $3,428,000 in the year ago period primarily as a result of a decrease of $210,000 in ultrasound products, a decrease of $188,000 in digital imaging and Axis image management systems offset by an increase of $67,000 in surgical products.
For the third quarter of fiscal 2016, margins remained steady at 49.0%. Marketing, general and administrative expenses decreased by 7.4% in the quarter primarily due to a reduction in force in October 2015, decreased hiring expense, travel expense, reduced international consulting fees and advertising costs offset by an increase in post-retirement expense.
For the quarter ended March 31, 2016, the Company reported a net loss of $81,000 or $0.01 per share. This compares to net income of $57,000 for the third quarter of fiscal 2015 or $0.01 per share. For the nine months of fiscal 2016, the Company reported a net loss of $640,000 or $0.08 per share. This compares to a net loss of $476,000 or $0.07 per share for the first nine months of the prior fiscal year.
At March 31, 2016, the Company had $619,000 of cash and no long-term debt. Inventory stood at $2.4 million at March 31, 2016. Consolidated marketing, general and administrative expenses from continuing operations decreased $356,000, or 8.5% to $3,837,000 during the nine months ended March 31, 2016, as compared to the same period of the prior fiscal year. The decrease is due a reduction in force, decreased hiring expense, reduced executive compensation, business tax, travel expense, reduced international consulting fees and advertising expenses offset by an increase in post-retirement expenses.
"Product revenues were weak in the quarter, in part due to lingering effects on sales orders resulting from last quarter's supply-chain shortages," commented Chief Executive Officer, Richard J. DePiano, Jr. "Furthermore, several international markets are being affected by challenging economic conditions and expanding regulatory requirements. Management continues to prioritize its supply-chain management, regulatory affairs and sales strategies, while continuing to review the cost side of the business, striving to reduce operating expenses as we close out fiscal 2016."
About Escalon Medical
Founded in 1987, Escalon Medical Corp. (ESMC) specializes in the development, marketing and distribution of ophthalmic diagnostic imaging and surgical products branded under the Sonomed Escalon name. Products include a variety of ophthalmic ultrasound, digital imaging and photography, and image management systems as well as surgical products including intraocular gases, fiber optic light guides and sources, and other surgical vitreoretinal instruments. The Company seeks to grow its ophthalmic business by further developing and diversifying its product offering through internal development programs, strategic partnerships, and the acquisition of technology so as to best leverage the Company's distribution capabilities. The Company has headquarters in Wayne, Pennsylvania and research and development, manufacturing and distribution operations in Lake Success, New York, New Berlin, Wisconsin and Stoneham, Massachusetts. For additional information visit www.escalonmed.com and www.sonomedescalon.com.
Forward Looking Statements
This press release contains statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. These statements are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to: develop, obtain regulatory clearance of and launch new products, implement its growth and marketing strategies; improve upon the operations of the Company including the ability to resolve supply-chain shortages; grow our remaining ophthalmic business unit; improve our financial position; implement cost reductions; generate cash; and identify, finance and enter into business relationships and acquisitions, if any, of which there can be no assurance. Other factors include uncertainties and risks related to: new product development, commercialization, manufacturing and market acceptance of new products; marketing acceptance of existing products in new markets; research and development activities, including failure to demonstrate clinical efficacy; delays by regulatory authorities, scientific and technical advances by the Company or third parties; introduction of competitive products; ability to reduce staffing and other costs and retain benefit of prior reductions; ability to refine the Company's internal sales organization and distributor channels; ability to fund operations from internally generated cash flow, and general economic conditions. Further information about these and other relevant risks and uncertainties may be found in the Company's report on Form 10-K for year ended June 30, 2015, and its other filings with the Securities and Exchange Commission, all of which are available from the Securities and Exchange Commission as well as other sources.
--financial tables to follow--
| ESCALON MEDICAL CORP. AND SUBSIDIARY | |||||||
| Unaudited Condensed Consolidated Statements of Operations | |||||||
| | | | | ||||
| | Three Months Ended | | Nine Months Ended | ||||
| | | | | | | | |
| | 2016 | | 2015 | | 2016 | | 2015 |
| | | | | | | | |
| Revenues, net | $ 3,097,022 | | $ 3,427,564 | | $ 8,867,179 | | $ 9,757,538 |
| | | | | | | | |
| Costs and expenses: | | | | | | | |
| Cost of goods sold | 1,579,762 | | 1,806,877 | | 4,554,248 | | 5,076,847 |
| Marketing, general and administrative | 1,225,296 | | 1,323,419 | | 3,836,776 | | 4,192,428 |
| Research and development | 370,178 | | 289,848 | | 1,112,696 | | 997,852 |
| Total costs and expenses | 3,175,236 | | 3,420,144 | | 9,503,720 | | 10,267,127 |
| | | | | | | | |
| Income (loss) from operations | (78,214) | | 7,420 | | (636,541) | | (509,589) |
| Other income (expense) | | | | | | | |
| Interest income | 51 | | 20 | | 88 | | 85 |
| Interest expense | (3,103) | | -- | | (3,103) | | -- |
| Total other income (loss) | (3,052) | | 20 | | (3,015) | | 85 |
| Net income (loss) from continuing operations | (81,266) | | 7,440 | | (639,556) | | (509,504) |
| Net income (loss) from discontinued operations | --- | | 49,102 | | --- | | 32,998 |
| Net income (loss) | $ (81,266) | | $ 56,542 | | $ (639,556) | | $ (476,506) |
| Basic and Diluted Net income (loss) per share | | | | | | | |
| Continuing operations | $ (0.01) | | $ -- | | $ (0.08) | | $ (0.07) |
| Discontinued operations | --- | | 0.01 | | --- | | 0.01 |
| Net income (loss) | $ (0.01) | | $ 0.01 | | $ (0.08) | | $ (0.06) Werbung Mehr Nachrichten zur Escalon Medical Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News |
